WO2023098888A1 - Ccr8 antigen binding unit and uses thereof - Google Patents

Ccr8 antigen binding unit and uses thereof Download PDF

Info

Publication number
WO2023098888A1
WO2023098888A1 PCT/CN2022/136276 CN2022136276W WO2023098888A1 WO 2023098888 A1 WO2023098888 A1 WO 2023098888A1 CN 2022136276 W CN2022136276 W CN 2022136276W WO 2023098888 A1 WO2023098888 A1 WO 2023098888A1
Authority
WO
WIPO (PCT)
Prior art keywords
seq
antigen binding
binding unit
cells
ccr8
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2022/136276
Other languages
English (en)
French (fr)
Inventor
Lishan Kang
Hongshui LIU
Lina Wang
Shang YIN
Shou LI
Bing WAN
Wenhua SHI
Min Chen
Xinchuan DAI
David BELLOVIN
Jing Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zai Lab Shanghai Co Ltd
Zai Lab US LLC
Original Assignee
Zai Lab Shanghai Co Ltd
Zai Lab US LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zai Lab Shanghai Co Ltd, Zai Lab US LLC filed Critical Zai Lab Shanghai Co Ltd
Priority to CA3239784A priority Critical patent/CA3239784A1/en
Priority to CN202280080188.8A priority patent/CN119072494A/zh
Priority to AU2022400921A priority patent/AU2022400921A1/en
Priority to IL313177A priority patent/IL313177A/en
Priority to JP2024533211A priority patent/JP2024541680A/ja
Priority to US18/715,739 priority patent/US20250034266A1/en
Priority to EP22900692.9A priority patent/EP4441098A4/en
Priority to KR1020247021902A priority patent/KR20240112929A/ko
Priority to MX2024006743A priority patent/MX2024006743A/es
Publication of WO2023098888A1 publication Critical patent/WO2023098888A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Definitions

  • CCR8 is a chemokine receptor that is selectively expressed on activated human tumor-resident Tregs, and these intratumoral CCR8+Tregs have been shown to drive immunosuppression that can lead to poor prognosis.
  • CCR8 can be targeted as a cancer immunotherapy by selectively depleting the intratumoral immunosuppressive Treg cells.
  • An antibody targeting human CCR8 can cause Treg depletion in tumor and renders the tumor sensitivity to a CPI therapy such as anti-PD-1 treatment.
  • the heavy chain CDR comprises HC-CDR1, HC-CDR2, and HC-CDR3, wherein the HC-CDR1, HC-CDR2, and HC-CDR3 each comprises a sequence selected from SEQ ID NO: 83-85 and 116-118.
  • the antigen binding unit is a monoclonal antibody, a humanized antibody, or a chimeric antibody.
  • the antigen binding unit of is a scFv, a Fab’, a single chain Fab (scFab’ ) , a Fd or a F (ab’) 2 , a sFC, a Fv, or a ccFv.
  • the antigen binding unit competes for binding to an epitope recognized by an antigen binding unit.
  • phrases "pharmaceutically acceptable” is employed herein to refer to those compounds, salts, compositions, dosage forms, etc., which are--within the scope of sound medical judgment--suitable for use in contact with the tissues of human beings and/or other mammals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
  • pharmaceutically acceptable means approved by a regulatory agency of the federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in mammals (e.g., animals) , and more particularly, in humans.
  • a polypeptide or amino acid sequence “derived from” a designated protein refers to the origin of the polypeptide.
  • the polypeptide has an amino acid sequence that is essentially identical to that of a polypeptide encoded in the sequence, or a portion thereof wherein the portion consists of at least 10-20 amino acids, or at least 20-30 amino acids, or at least 30-50 amino acids, or which is immunologically identifiable with a polypeptide encoded in the sequence.
  • This terminology also includes a polypeptide expressed from a designated nucleic acid sequence.
  • a light chain CDR comprises three light chain CDRs, which can be referred to as light chain CDR-1, light chain CDR-2, and light chain CDR-3 respectively.
  • a group of CDRs present on a common light chain can collectively be referred to as light chain CDRs.
  • Polyclonal or monoclonal antigen binding units or antibodies can be produced from animals which have been genetically altered to produce human immunoglobulins.
  • a transgenic animal can be produced by initially producing a “knock-out” animal which does not produce the animal's natural antibodies, and stably transforming the animal with a human antibody locus (e.g., by the use of a human artificial chromosome) . In such cases, only human antibodies are then made by the animal. Techniques for generating such animals, and deriving antibodies therefrom, are described in U.S. Pat. Nos. 6,162,963 and 6,150,584, incorporated fully herein by reference. Such antibodies can be referred to as human xenogenic antibodies.
  • Conservative amino acid substitutions include substitutions within the following groups: glycine, alanine; valine, isoleucine, leucine; aspartic acid, glutamic acid; asparagine, glutamine; serine, threonine; lysine, arginine; and phenylalanine, tyrosine. While conservative substitutions do effectively change one or more amino acid residues contained in the polypeptide to be produced, the substitutions are not expected to interfere with the antigen-binding activity of the resulting antigen binding units to be produced. Nucleotide substitutions that do not alter the amino acid residues encoded are useful for optimizing gene expression in different systems. Suitable substitutions are known to those of skill in the art and are made, for instance, to reflect preferred codon usage in the expression systems.
  • the vectors may contain a selectable marker (for example, a gene encoding a protein necessary for the survival or growth of a host cell transformed with the vector) , although such a marker gene can be carried on another polynucleotide sequence co-introduced into the host cell.
  • a selectable marker for example, a gene encoding a protein necessary for the survival or growth of a host cell transformed with the vector
  • expression of the antigen binding units can be determined using any nucleic acid or protein assay known in the art.
  • the presence of transcribed mRNA of light chain CDRs or heavy chain CDRs, or the antigen binding unit can be detected and/or quantified by conventional hybridization assays (e.g. Northern blot analysis) , amplification procedures (e.g. RT-PCR) , SAGE (U.S. Pat. No. 5,695,937) , and array-based technologies (see e.g. U.S. Pat. Nos. 5,405,783, 5,412,087 and 5,445,934) , using probes complementary to any region of antigen binding unit polynucleotide.
  • hybridization assays e.g. Northern blot analysis
  • amplification procedures e.g. RT-PCR
  • SAGE U.S. Pat. No. 5,695,937
  • array-based technologies see e.g. U.S. Pat. Nos. 5,405,783, 5,412,
  • methods of eradicating an immune cell comprising contacting a population of immune cells with an effective amount of the pharmaceutical composition described herein are provided.
  • treatment of cancer can be evidenced by reduced tumor volume.
  • tumor volume is reduced by a percentage within the range of 1%to 100%.
  • tumor volume is reduced by about 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%.
  • tumor volume is reduced by at least about 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%.
  • the medicaments are used in the form of salts (e.g., as alkali metal or amine salts or as acid addition salts) or as esters (e.g., lower alkyl esters) or as solvates (e.g., hydrates) to optimize the activity and/or stability of the medicament.
  • salts e.g., as alkali metal or amine salts or as acid addition salts
  • esters e.g., lower alkyl esters
  • solvates e.g., hydrates
  • the antigen binding units described herein can be used in combination with the agents disclosed herein or other suitable agents, depending on the condition being treated. Hence, in some embodiments the one or more antigen binding units of the disclosure will be co-administered with other agents as described above.
  • the antigen binding units described herein are administered with the second agent simultaneously or separately.
  • This administration in combination can include simultaneous administration of the two agents in the same dosage form, simultaneous administration in separate dosage forms, and separate administration. That is, an antigen binding unit described herein and any of the agents described above can be formulated together in the same dosage form and administered simultaneously.
  • an antigen binding unit of the disclosure and any of the agents described above can be simultaneously administered, wherein both the agents are present in separate formulations.
  • Antibodies were prepared with 3-fold serial dilution ranging from 100 nM to 0.0017 nM or from 25.3165 nM to 0.0004 nM in FACS buffer. 433H was set as a positive control. After primary antibody incubation, cells were washed by FACS buffer for three times. Then, cells were stained with secondary antibody (Alexa Flu647-conj ⁇ gated rabbit anti-mouse IgG, Jackson ImmunoResearch, #315606046) at 1: 600 dilution in FACS buffer, incubated for 0.5 hour at 4°C. Alexa Fluor 647 signals of the stained cells were detected by BD FACS Celesta and the MFI were determined. FlowJo software was used for analysis. Data was plotted as the logarithm of antibody concentration versus mean fluorescence signals. EC 50 values were calculated in GraphPad Prism 8 (GraphPad Software) using a log (agonist) vs. response-Variable slope (4 parameters) curve fit.
  • the binding affinities of humanized 149 antibodies were tested using HEK293-human CCR8 and HEK293-Cynomolgus CCR8 cells.
  • the blocking activities of humanized 149 antibodies were tested using CHO-K1-human CCR8 cells.
  • Hu149-4 and Hu149-9 showed best binding activities among the humanized antibodies on HEK293-human CCR8 and HEK293-Cynomolgus CCR8 cells in two separate experiment settings.
  • Hu149-4 and Hu149-9 showed most potent blocking activities among the humanized antibodies on CHO-K1-human CCR8 cells, the IC 50 s were 0.137 nM and 0.119 nM, respectively.
  • CHO-K1 cells co-expressing human CCR8 tagged with ProLink (PK) and Enzyme Acceptor (EA) were incubated with antibody or CCL1 (CN-07, Almac) for 90 minutes before adding detection reagent (93-0001, DiscoverX) .
  • CCL1 induced ⁇ -arrestin recruitment in a dose dependent manner and the EC 50 was 0.288 nM.
  • the reference antibody 433H, CM149 or Hu149-4 did not induce ⁇ -arrestin recruitment (FIG. 6) .
  • Hu149-4-mIgG2a, Hu149-9-mIgG2a and 433H blocked CCL1 induced cell migration.
  • the IC50s were 2.95 nM, 1.92 nM and 1.25 nM, respectively (FIG. 7, Table 18) .
  • Th term “NA” indicates “Not Applicable” .
  • Hu149-11G1m was more potent than Hu10A11-1 in inhibiting ⁇ -Arrestin recruitment with IC 50 s of 2.09 nM and 37.1 nM, and maximum inhibition rates of 72.7%and 43.6%, respectively.
  • Hu149-11G1m and Hu149-12 G1m showed similar inhibitory activities of ⁇ -Arrestin recruitment, the IC 50 s were 2.09 nM and 1.16 nM, respectively.
  • This study examined anti-tumor efficacy of a CCR8 antibody as a single agent and in a combination with a PD-1 antibody in vivo. More specifically, the efficacy of Hu149-11G1m in the human CCR8 transgenic mice that carry MC38 tumors was tested.
  • the MC38 is a murine colon carcinoma cell line. Mice were inoculated subcutaneously with MC38, and tumor-bearing mice were then administered Hu149-11G1m twice per week at doses of 3 mg/kg as a single agent or in a combination with anti-PD-1 antibody (Biocell cat#CP151) at the doses of 5 mg/kg. Tumor growth was monitored throughout the study and the survival rate was recorded at the end of the study. The mice that achieved complete tumor regression were re-challenged with tumor to test the sustainability of the anti-tumor effects. As detailed below, in combo treatment group, a superior survival rate was achieved and a significant Treg depletion was observed.
  • mice continued to be monitored for a health check and tumor volume measurement twice a week. All the mice without excessive tumor burden (TV ⁇ 1500 mm 3 ) would be maintained for the assessment of survival. As detailed below, in combo treatment group, a better survival rate was achieved and a significant Treg depletion was observed

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PCT/CN2022/136276 2021-12-02 2022-12-02 Ccr8 antigen binding unit and uses thereof Ceased WO2023098888A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
CA3239784A CA3239784A1 (en) 2021-12-02 2022-12-02 Ccr8 antigen binding unit and uses thereof
CN202280080188.8A CN119072494A (zh) 2021-12-02 2022-12-02 Ccr8抗原结合单元及其用途
AU2022400921A AU2022400921A1 (en) 2021-12-02 2022-12-02 Ccr8 antigen binding unit and uses thereof
IL313177A IL313177A (en) 2021-12-02 2022-12-02 CCR8 antigen binding unit and its uses
JP2024533211A JP2024541680A (ja) 2021-12-02 2022-12-02 Ｃｃｒ８抗原結合ユニット及びその使用
US18/715,739 US20250034266A1 (en) 2021-12-02 2022-12-02 Ccr8 antigen binding unit and uses thereof
EP22900692.9A EP4441098A4 (en) 2021-12-02 2022-12-02 CCR8 antigen-binding unit and uses thereof
KR1020247021902A KR20240112929A (ko) 2021-12-02 2022-12-02 Ccr8 항원 결합 단위 및 그들의 용도
MX2024006743A MX2024006743A (es) 2021-12-02 2022-12-02 Unidad de union a antigeno ccr8 y usos de los mismos.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/134930 2021-12-02
CN2021134930 2021-12-02

Publications (1)

Publication Number Publication Date
WO2023098888A1 true WO2023098888A1 (en) 2023-06-08

Family

ID=86611552

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2022/136276 Ceased WO2023098888A1 (en) 2021-12-02 2022-12-02 Ccr8 antigen binding unit and uses thereof

Country Status (11)

Country Link
US (1) US20250034266A1 (https=)
EP (1) EP4441098A4 (https=)
JP (1) JP2024541680A (https=)
KR (1) KR20240112929A (https=)
CN (1) CN119072494A (https=)
AU (1) AU2022400921A1 (https=)
CA (1) CA3239784A1 (https=)
IL (1) IL313177A (https=)
MX (1) MX2024006743A (https=)
TW (1) TW202342533A (https=)
WO (1) WO2023098888A1 (https=)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024165468A1 (en) 2023-02-06 2024-08-15 Bayer Aktiengesellschaft Combination of ccr8 antibodies with dgk inhibitors in the treatment of cancer
WO2024240224A1 (zh) * 2023-05-23 2024-11-28 再鼎医药(上海)有限公司 包含抗ccr8抗体的制剂及其用途
WO2024248037A1 (ja) 2023-05-30 2024-12-05 塩野義製薬株式会社 Ｃｃｒ８を抗原として認識する二重特異性抗体
WO2025113643A1 (en) 2023-12-01 2025-06-05 Gilead Sciences Inc. Anti-fap-light fusion protein and use thereof
WO2025145207A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg-depleting agent
WO2025140619A1 (zh) * 2023-12-29 2025-07-03 苏州泽璟生物制药股份有限公司 包含ccr8抗原结合结构域的多特异性抗体
WO2025186043A1 (en) 2024-03-06 2025-09-12 Bayer Aktiengesellschaft Pharmaceutical formulation for anti-ccr8 antibodies
WO2025259871A1 (en) 2024-06-14 2025-12-18 Gilead Sciences, Inc. Anti-ccr8 antibodies and uses thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007044756A2 (en) * 2005-10-11 2007-04-19 Icos Corporation Monoclonal antibodies recognizing human ccr8
US20190092875A1 (en) * 2014-04-28 2019-03-28 Memorial Sloan Kettering Cancer Center Depleting tumor-specific tregs
CN110835371A (zh) * 2018-08-19 2020-02-25 普米斯生物技术(苏州)有限公司 抗ccr8单克隆抗体及其应用
WO2021152186A2 (en) * 2020-06-26 2021-08-05 Bayer Aktiengesellschaft Ccr8 antibodies for therapeutic applications
WO2021163064A2 (en) * 2020-02-14 2021-08-19 Jounce Therapeutics, Inc. Antibodies and fusion proteins that bind to ccr8 and uses thereof
EP3903817A1 (en) * 2018-12-27 2021-11-03 Shionogi & Co., Ltd. Novel anti-ccr8 antibody

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021244200A1 (en) * 2020-03-23 2022-11-24 Bristol-Myers Squibb Company Anti-CCR8 antibodies for treating cancer

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007044756A2 (en) * 2005-10-11 2007-04-19 Icos Corporation Monoclonal antibodies recognizing human ccr8
US20190092875A1 (en) * 2014-04-28 2019-03-28 Memorial Sloan Kettering Cancer Center Depleting tumor-specific tregs
CN110835371A (zh) * 2018-08-19 2020-02-25 普米斯生物技术(苏州)有限公司 抗ccr8单克隆抗体及其应用
EP3903817A1 (en) * 2018-12-27 2021-11-03 Shionogi & Co., Ltd. Novel anti-ccr8 antibody
WO2021163064A2 (en) * 2020-02-14 2021-08-19 Jounce Therapeutics, Inc. Antibodies and fusion proteins that bind to ccr8 and uses thereof
WO2021152186A2 (en) * 2020-06-26 2021-08-05 Bayer Aktiengesellschaft Ccr8 antibodies for therapeutic applications

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CAMPBELL JOSEPH R., MCDONALD BRYAN R., MESKO PAUL B., SIEMERS NATHAN O., SINGH PRITI B., SELBY MARK, SPROUL TIM W., KORMAN ALAN J.: "Fc-Optimized Anti-CCR8 Antibody Depletes Regulatory T Cells in Human Tumor Models", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 81, no. 11, 1 June 2021 (2021-06-01), US, pages 2983 - 2994, XP055866698, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-20-3585 *
See also references of EP4441098A4 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024165468A1 (en) 2023-02-06 2024-08-15 Bayer Aktiengesellschaft Combination of ccr8 antibodies with dgk inhibitors in the treatment of cancer
WO2024240224A1 (zh) * 2023-05-23 2024-11-28 再鼎医药(上海)有限公司 包含抗ccr8抗体的制剂及其用途
WO2024248037A1 (ja) 2023-05-30 2024-12-05 塩野義製薬株式会社 Ｃｃｒ８を抗原として認識する二重特異性抗体
WO2025113643A1 (en) 2023-12-01 2025-06-05 Gilead Sciences Inc. Anti-fap-light fusion protein and use thereof
WO2025145207A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg-depleting agent
WO2025140619A1 (zh) * 2023-12-29 2025-07-03 苏州泽璟生物制药股份有限公司 包含ccr8抗原结合结构域的多特异性抗体
WO2025186043A1 (en) 2024-03-06 2025-09-12 Bayer Aktiengesellschaft Pharmaceutical formulation for anti-ccr8 antibodies
WO2025259871A1 (en) 2024-06-14 2025-12-18 Gilead Sciences, Inc. Anti-ccr8 antibodies and uses thereof

Also Published As

Publication number Publication date
AU2022400921A1 (en) 2024-06-27
CA3239784A1 (en) 2023-06-08
KR20240112929A (ko) 2024-07-19
EP4441098A4 (en) 2026-03-04
JP2024541680A (ja) 2024-11-08
MX2024006743A (es) 2024-08-27
EP4441098A1 (en) 2024-10-09
TW202342533A (zh) 2023-11-01
US20250034266A1 (en) 2025-01-30
IL313177A (en) 2024-07-01
CN119072494A (zh) 2024-12-03

Similar Documents

Publication Publication Date Title
WO2023098888A1 (en) Ccr8 antigen binding unit and uses thereof
US11267885B2 (en) CD47 antigen binding unit and uses thereof
JP5039027B2 (ja) 結腸癌および膵臓癌のための、組換え型モノクローナル抗体および対応する抗原
KR20210003808A (ko) 항-클라우딘 18.2 항체 및 이의 사용
JP2020504095A (ja) 抗ＰＤ−Ｌ１抗体との組み合わせのための抗Ｔｉｍ−３抗体
JP2013531655A (ja) Ｓ１００ａ４抗体およびその治療上の使用
EP3404040B1 (en) Anti-myl9 antibody
RU2694903C1 (ru) Антитела к CD43 и их применение для лечения рака
WO2008153636A1 (en) Phospho-specific antibodies to p13k regulatory subunit and uses thereof
US9163080B2 (en) Anti-single-chain type IV collagen polypeptide antibody, pharmaceutical drug, diagnostic, preventive, or therapeutic drug for tumour containing the antibody
HK40120943A (zh) Ccr8抗原结合单元及其用途
RU2780859C2 (ru) Cd47-антигенсвязывающая единица и ее применение
US20240174741A1 (en) Il-38-specific antibodies
US20130302341A1 (en) Therapeutic and diagnostic applications targeting tnk-1
KR20240176948A (ko) 소세포폐암 진단 및 치료를 위한 타겟으로서 클라우딘-3의 용도
HK40015810A (en) Cd47 antigen binding unit and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22900692

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2024533211

Country of ref document: JP

Kind code of ref document: A

Ref document number: 3239784

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 202280080188.8

Country of ref document: CN

Ref document number: 18715739

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2022400921

Country of ref document: AU

Ref document number: AU2022400921

Country of ref document: AU

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112024011014

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2022400921

Country of ref document: AU

Date of ref document: 20221202

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20247021902

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2022900692

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2022900692

Country of ref document: EP

Effective date: 20240702

ENP Entry into the national phase

Ref document number: 112024011014

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20240531